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Abstract  
Metabolic reprogramming has been described in rapidly growing tumors, which are thought to mostly contain 
fast-cycling cells (FCCs) that have impaired mitochondrial function and rely on aerobic glycolysis. Here, we 
characterize the metabolic landscape of glioblastoma (GBM) and explore metabolic specificities as targetable 
vulnerabilities. Our studies highlight the metabolic heterogeneity in GBM, in which FCCs harness aerobic 
glycolysis, and slow-cycling cells (SCCs) preferentially utilize mitochondrial oxidative phosphorylation for their 
functions. SCCs display enhanced invasion and chemoresistance, suggesting their important role in tumor 
recurrence. SCCs also demonstrate increased lipid contents that are specifically metabolized under glucose-
deprived conditions. Increased fatty acid transport in SCCs is targetable by pharmacological inhibition or 
genomic deletion of FABP7, both of which sensitize SCCs to metabolic stress. Furthermore, FABP7 inhibition, 
whether alone or in combination with glycolysis inhibition, leads to overall increased survival. Our studies 
reveal the existence of GBM cell subpopulations with distinct metabolic requirements and suggest that FABP7 
is central to lipid metabolism in SCCs and that targeting FABP7-related metabolic pathways is a viable 
therapeutic strategy.  
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Introduction 
Intratumoral heterogeneity, which manifests on genetic, transcriptional, and functional levels, is increasingly 
recognized as a determinant of therapy resistance and disease recurrence. Indeed, tumor recurrence results 
from the ability of specific tumor subpopulations to resist treatment and expand. As has been shown for several 
malignancies, including glioblastoma (GBM), conventional cancer therapies most effectively eliminate rapidly 
dividing cells while sparing slower proliferating populations (Campos, Gal et al., 2014, Dembinski & Krauss, 
2009, Gao, Choi et al., 2010, Graham, Jorgensen et al., 2002, Moore, Houghton et al., 2012, Oshimori, 
Oristian et al., 2015, Pece, Tosoni et al., 2010, Roesch, Fukunaga-Kalabis et al., 2010, Zeuner, 
Francescangeli et al., 2014). GBM represents a prototypical example of heterogeneous cancer and is one of 
the most lethal malignancies, with a median survival of approximately 15-18 months despite multimodal 
therapy (Stupp, Mason et al., 2005, Stupp, Taillibert et al., 2015). This dismal prognosis is attributable to 
therapy-resistant GBM cells that drive recurrence, and the identification and characterization of these cellular 
subpopulations and their dynamic are essential for the development of more effective treatments.  
A recent study demonstrated a proliferative hierarchy in human GBM, with slow-cycling, cancer stem-
like cells giving rise to rapidly proliferating progenies via asymmetric division, which in turn generate limited-
lived and non-proliferative offspring	(Lan, Jorg et al., 2017). A similar hierarchy has been proposed in a mouse 
model of glioma, with TMZ-resistant, slow-dividing cancer stem cells driving long-term tumor growth via the 
generation of a rapidly growing transient population of cells	(Chen, Li et al., 2012). These results were also 
confirmed in human GBM	(Campos et al., 2014). Similarly, Vanner and colleagues showed that quiescent, 
SOX2-positive cells drive long-term tumor propagation and relapse in a sonic hedgehog subgroup of 
medulloblastoma	(Vanner, Remke et al., 2014). Using single-cell RNA sequencing, Tirosh et al. reported a 
similar cellular hierarchy that is driven by developmental programs in oligodendroglioma	(Tirosh, Venteicher et 
al., 2016c).  
We have previously reported the existence, isolation, and functional characterization of fast-cycling 
cells (FCCs) and slow-cycling cells (SCCs) in GBM (Deleyrolle, Harding et al., 2011, Deleyrolle, Rohaus et al., 
2012). We found that human GBM SCCs are consistently enriched in cancer stem cell markers in vitro. This 
SCC population is enriched in tumor-initiating cells, leading to enhanced tumorigenicity compared to the overall 
tumor population. SCCs were also identified and isolated in vivo and demonstrated all the key functional and 
phenotypic characteristics defining cancer stem cells, thus making them a clinically relevant target for new 
GBM treatment approaches (Deleyrolle et al., 2011).  
 According to the Warburg hypothesis (Warburg, 1926), tumorigenesis is partly driven by an impairment 
of mitochondrial function and oxidative phosphorylation (OxPhos). These alterations result in the Warburg 
effect, which is characterized by cancer cells generating most of their energy from glucose fermentation, i.e., 
aerobic glycolysis, with a limited ability to perform nutrient oxidation (Koppenol, Bounds et al., 2011). This 
metabolic reprogramming is thought to be an adaptation mechanism of rapidly growing tumor cells to cover 
their increasing energy demands. The intrinsic cellular heterogeneity of GBM raises the question as to whether 
the different cellular subpopulations (e.g., FCCs and SCCs) are restricted to glucose fermentation or other 
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metabolic pathways for their survival and proliferation. Interestingly, recent studies have demonstrated residual 
activity of mitochondrial function in GBM cells (Lin, Patel et al., 2017, Marin-Valencia, Yang et al., 2012, 
Mashimo, Pichumani et al., 2014), suggesting that some of these cells might utilize mitochondrial OxPhos. 
However, the precise nature of the GBM cellular compartments harboring various metabolic specificities still 
needs to be established.  
Here, we demonstrate that functionally different GBM cell subpopulations depend on distinct metabolic 
pathways for their growth and survival. Importantly, GBM SCCs display unique phenotypic traits, 
chemoresistance, and metabolic profiles that are divergent from those of FCCs and engage metabolic 
pathways that overlap with those found in recurrent GBM. Our work uncovers a previously unidentified 
metabolic dichotomy in GBM, with FCCs depending on glucose metabolism and SCCs relying on oxidative 
phosphorylation and lipid metabolism for their growth and survival. We show that blocking the specific energy 
pathways utilized by GBM FCCs and SCCs inhibits overall tumor growth. Our studies also highlight the SCC 
subpopulation as a determinant for GBM’s resistance to metabolic treatments targeting the Warburg effect and 
identify in this population new candidate therapeutic targets including FABP7. 
 
Results 
SCCs display migration, invasion, and chemoresistance characteristics that promote GBM recurrence  
We have previously shown that GBM SCCs are enriched in stem-like cells that are associated with greater 
tumorigenicity (Deleyrolle et al., 2011). Additionally, using gene set enrichment analysis, we have 
demonstrated that SCCs overexpress a gene module defined as a stem cell signature (Fig EV1A) (Wong, Liu 
et al., 2008). GBM cells with a stem-like cell phenotype have also been associated with higher migration and 
invasion capabilities (Siebzehnrubl, Silver et al., 2013). Therefore, we tested the hypothesis that GBM cell 
proliferation rates might be inversely correlated with migration/invasion potentials in vitro and in vivo. SCCs 
and FCCs from patient-derived primary GBM Line 0 (L0), Line 1 (L1), and Line 2 (L2) (Deleyrolle et al., 2011) 
were separated using a flow cytometry-based label retention paradigm, as previously described (Deleyrolle et 
al., 2011) (Fig EV1B). All experiments were conducted immediately after FAC-sorting of the SCC and FCC 
populations. The migration abilities of these cellular subpopulations were quantified directly after sort using in 
vitro scratch assays (Siebzehnrubl, Silver et al., 2013). Within 24 hours, SCC migration distances were 
significantly larger than FCCs’ (Fig 1A) for all three cell lines, even though FCCs have higher proliferation rates 
(Deleyrolle et al., 2011).  
Importantly, ten weeks after intracranial xenotransplantation in mice (which represents the approximate 
survival endpoint for FCC and non-SCC implanted animals), SCCs had generated more invasive tumors than 
FCCs, for two patient-derived GBM cell lines (Fig 1B, Fig EV1C). In order to directly compare the invasion 
potential of SCCs and FCCs in vivo, we lentivirally transduced SCCs with GFP and FCCs with RFP, and 
intracranially implanted these together at a ratio of 1:1 into recipient mice. This enabled assessing whether the 
observed greater invasion of SCCs was due to slower tumor growth and thus smaller tumor size, whether 
FCC- derived tumors would appear more invasive when observed at earlier stages of tumor formation, and 
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whether invasion of FCCs would be influenced by SCCs in their environment. We analyzed these tumors six 
weeks after implantation to avoid tumor mass expansion potentially displacing signs of invasion. In all animals, 
SCCs generated a network of invasive cells infiltrating the brain parenchyma and extending long processes 
that were consistent with tumor microtubes (Osswald, Jung et al., 2015), while FCCs generated more 
contained tumor masses (Fig 1C). These results show that invasion is intrinsic to SCCs, while FCCs generate 
non- infiltrating tumor masses.  
Epithelial-to-mesenchymal transition (EMT), and in particular the EMT transcription factor zinc-finger E-
box binding homeobox 1 (ZEB1), has been frequently associated with a loss of cell-to-cell contact and the 
distant spreading of tumors (Siebzehnrubl et al., 2013, Singh & Settleman, 2010). Moreover, ZEB1 promotes 
cancer cell stemness (Aigner, Dampier et al., 2007, Chaffer, Marjanovic et al., 2013, Shimono, Zabala et al., 
2009, Wellner, Schubert et al., 2009), and the co-expression of SOX2, OLIG2, and ZEB1 transformed tumor-
suppressor-deficient murine astrocytes into glioma-initiating cells in the absence of an upstream oncogene 
(Singh, Kollipara et al., 2017). Therefore, we hypothesized that ZEB1 may regulate SCC invasion and tested 
whether this transcription factor was differentially expressed in SCCs and FCCs in vivo. We found that FCC-
derived, non-invasive tumors were devoid of ZEB1, while ZEB1-immunoreactive cells were consistently found 
throughout SCC-derived invasive tumors (Fig EV1D). To determine whether the higher ZEB1 levels in SCCs 
are linked to these cells’ greater capability for migration and invasion, we isolated SCC and FCC populations 
from control and ZEB1 knockdown cells. The invasion of tumor derived from ZEB1 knockdown SCC in 
orthotopic xenografts was greatly reduced compared to control SCC-derived tumors (Fig 1D, Fig EV1E). 
These results show that ZEB1 is necessary for migration and invasion of SCCs. 
Because ZEB1 and other EMT regulators have been shown to induce chemoresistance in GBM 
(Depner, Zum Buttel et al., 2016, Qi, Song et al., 2012, Siebzehnrubl et al., 2013), we next tested whether 
GBM SCCs, which are enriched in ZEB1, are more resistant to therapy than FCCs, as has been demonstrated 
for other quiescent subsets of GBM cells (Chen et al., 2012) (Campos et al., 2014). We evaluated the in vitro 
effects of the standard-of-care chemotherapeutic drug temozolomide (TMZ) on the cell viabilities of the total 
tumor cell populations as well as FCCs and SCCs using MTT assays. While all three L0, L1, and L2 total cell 
populations displayed some sensitivity to TMZ, L0 was the most sensitive and L2 the most resistant line. 
Importantly, the SCCs from all three patient-derived GBM cells lines showed higher resistance to TMZ than the 
corresponding cell line’s FCCs (Fig 1E). Moreover, by repeatedly exposing these primary GBM lines to TMZ, 
we selected for TMZ-resistant cell populations (TMZR) with expansion rates and TMZ resistance profiles similar 
to SCCs’ (Fig EV1F-G). TMZR and SCCs also showed comparable migration and invasion potential (Fig 
EV1H-J). These results further underscore the link between GBM cell proliferation rate, invasiveness, and 
chemoresistance.  
We next tested whether SCCs were more chemoresistant than the rest of the GBM cell population in 
vivo. We treated tumor-bearing animals, orthotopically grafted with either SCCs or FCCs, with clinically 
relevant TMZ concentrations (20 mg/kg) (Zhou, Guo et al., 2007). TMZ treatment prolonged the median 
survival of animals implanted with L2 FCCs, but did not improve the survival of the L2 SCC-implanted group 
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(Fig 1D). Similarly, TMZ treatment lengthened the survival of L0 FCC-grafted animals, but had significantly 
smaller effects in L0 SCC-grafted animals (Fig 1E). These results further demonstrate that GBM SCCs are 
more resistant to TMZ than the rest of the tumor cell population and thus more likely to escape standard-of-
care therapy (Fig EV1I). Together, our findings support a critical role of SCCs in both GBM invasion and 
chemoresistance and thus in tumor recurrence. 
 
Treatment-resistant/recurrent tumors share metabolic gene signatures with SCCs  
Based on the hypothesis that SCCs might contribute to tumor recurrence, and to identify the molecular 
mechanisms involved in their survival and growth, we investigated the molecular pathways that are 
characteristic of recurrent GBM tumors. We compared the RNA sequencing data of 153 primary and 14 
recurrent GBM patient tumors from the TCGA database (Cancer Genome Atlas Research, 2008) and identified 
several genes that were significantly up-regulated in recurrent tumors compared to primary tumors (Fig 2A, 
Table EV1). Using the String database (Szklarczyk, Franceschini et al., 2015), we found that lipid metabolism 
was one of the top 5 most significantly enriched gene pathway groups in GBM recurrent tumors (GO:0033993, 
Fig EV2A, Table EV2). Interestingly, lipid metabolism constitutes the main source for mitochondrial energy 
production, and we found significantly higher mRNA expression levels of multiple genes involved in 
mitochondrial OxPhos, the tricarboxylic acid (TCA) cycle, and pyruvate and antioxidant metabolism in recurrent 
GBM (fold change > 2, Mann-Whitney test, p < 0.05; Fig EV2B-C, Table EV3). Notably, GBM SCCs displayed 
these specific metabolic signatures, further supporting SCCs’ influential presence and role in tumor recurrence 
(Fig 2B). We also found that the mRNA expression levels of genes involved in the glycolytic/gluconeogenesis 
pathways were down-regulated in recurrent tumors (fold change > 2, Mann-Whitney test, p < 0.05; Table EV4). 
Together, these data support the presence of metabolic heterogeneity and plasticity in GBM. 
 In addition, we performed in silico analysis of single cell RNA sequencing data from existing glioma 
databases (Venteicher, Tirosh et al., 2017) to further confirm GBM’s intra-tumoral heterogeneity and identified 
various clusters of cells demonstrating gene signatures for OxPhos and glycolysis (Fig 2C, Table EV5). We 
propose that the cluster “OxPhos high /Glycolysis high” represents cells undergoing glycolysis via glucose 
oxidation, and the cluster “OxPhos high /Glycolysis low” indicates cells oxidizing nutrients other than glucose, 
such as lipids or amino acids. The “OxPhos low /Glycolysis high” cluster reveals cells that follow the Warburg 
effect while cells with the “OxPhos low /Glycolysis low” signature use alternative metabolic pathways (Fig 2C). 
We classified cells from this single cell RNA sequencing data into slow and fast-cycling clusters based on the 
relative expression of cell cycle G1/S (x axis) and G2/M (y axis)-associated gene sets (Fig EV2D), as 
previously described (Patel, Tirosh et al., 2014, Tirosh, Izar et al., 2016a, Tirosh, Venteicher et al., 2016b). We 
then evaluated the lipid signature identified in recurrent GBM tumors and our GBM cell line SCCs and found 
overrepresentation of the lipid gene set in the slow-cycling cluster defined from the single cell RNA sequencing 
data (Fig EV2E). 
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Together, our analyses demonstrate the existence of metabolic heterogeneity in GBM with common 
and specific metabolic pathways, particularly related to OxPhos and lipid metabolism, being overrepresented in 
SCCs and recurrent tumors.  
 
SCCs display increased mitochondrial activity and OxPhos   
As our results suggest that GBM SCCs contribute to the metabolic gene signature of recurrent tumors (i.e., 
increased mitochondrial and lipid pathway genes), we next compared the amount, components, and activity of 
SCC and FCC mitochondria. First, in vivo tumors derived from SCC or FCC xenografts were immunostained 
with the mitochondrial marker MTCO2 and showed a higher number of mitochondria in SCC-derived tumors 
(Fig 3A). This finding was confirmed by electron microscopy, which demonstrated more mitochondria per cell 
in SCCs than in FCCs (Fig 3B-C and Fig EV3A). We also found that MitoTracker Green accumulated 
significantly more in GBM SCCs than FCCs (Fig 3D, Fig EV3B), indicating that SCCs possess a higher 
mitochondrial mass (De Paepe, 2012). 
Second, we compared the mitochondria components between GBM SCCs and FCCs. We examined 
the voltage-dependent anion-selective channels (VDACs) in these two populations. VDACs are a class of porin 
ion channels that are located on the outer mitochondrial membrane and play a key role in regulating metabolic 
and energetic flux across that membrane (Hoogenboom, Suda et al., 2007). VDACs are involved in the 
transport of ATP, ADP, pyruvate, malate, and other metabolites, thus interacting extensively with enzymes 
from various metabolic pathways (Blachly-Dyson & Forte, 2001). Notably, VDACs are important regulators of 
Ca2+ transport in and out of the mitochondria, and because Ca2+ is a co-factor for metabolic enzymes such as 
pyruvate dehydrogenase and isocitrate dehydrogenase, energetic production through OxPhos and 
homeostasis are both affected by VDACs’ permeability to Ca2+ (Shoshan-Barmatz & Gincel, 2003). Of the 
three VDAC isoforms, VDAC1 is the main Ca2+ ion transport channel and the most abundantly transcribed 
(Chu, Goldman et al., 2014). Interestingly, we found consistent VDAC1 staining in GBM SCCs by 
immunofluorescence (Fig 3E) and flow cytometry (Fig 3F), while FCCs displayed significantly weaker VDAC1 
expression. Of note, we also found an increased expression of electron transport chain (ETC) enzymatic 
complexes, particularly NADH dehydrogenase (complex I) and ATP synthase (complex V), in SCCs compared 
to FCCs (Fig 3G-H), suggesting higher OxPhos activity in GBM SCCs than in FCCs.   
We next compared mitochondrial respiratory activities between GBM SCCs and FCCs. Mitochondrial 
respiration functional assays with MitoTracker Orange, a dye that accumulates in active mitochondria where it 
gets oxidized, revealed significantly higher levels of reactive oxygen species (ROS) in SCCs than in FCCs (Fig 
3I, Fig EV3C). Of note, even though the majority of cellular ROS are normally produced by mitochondria, 
approximately a quarter can be produced from protein and lipid metabolism in the endoplasmic reticulum (ER) 
of glioma cells (Salazar-Ramiro, Ramirez-Ortega et al., 2016). Therefore, the differences in ROS levels 
observed from our MitoTracker Orange assays could have been due to either higher mitochondrial OxPhos 
activity or greater ER protein/lipid metabolism in SCCs than in FCCs. However, greater mitochondrial OxPhos 
activity is supported by our experimental results, which show elevated mitochondrial membrane potential and 
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higher levels of mitochondrial respiratory energetics in SCCs compared to FCCs using the MitoProbe DilC1 
assay (Fig 3J, Fig EV3D). In addition, we conducted Seahorse experiments to directly compare the metabolic 
activities between SCC and FCC populations. Basal and maximal oxygen consumption rates, as well as ATP 
production, were significantly higher in SCCs compared to FCCs for L0, L1, and L2 (Fig 3K-N, Fig EV3E-F). 
Together, our data show that SCCs display heightened mitochondrial and OxPhos activities compared to 
FCCs. 
 
A metabolic dichotomy exists between GBM SCCs and FCCs 
 Maintaining mitochondrial OxPhos activities may confer SCCs broader metabolic capacities beyond 
aerobic glycolysis. We had previously shown that GBM cells were sensitive to glucose deprivation 
(Martuscello, Vedam-Mai et al., 2016) and next examined whether GBM SCCs and FCCs displayed the same 
glucose dependencies. We tested the response of SCCs and FCCs to high (500 mg/dL) or 
lowered/physiological (90-110 mg/dL) glucose levels in normoxic conditions. Flow cytometry revealed 
increased cell death in FCCs, but not SCCs, following glucose restriction (Fig 4A, Fig EV4A), indicating that 
SCCs do not rely on glycolysis for energy production and survival. In addition, we found that SCCs are less 
sensitive than FCCs to the pharmacological inhibitor of glycolysis, 2-deoxyglucose (2-DG), complementing the 
results obtained using glucose restriction (Fig 4B, Fig EV4B). In support of these observations, we found, 
using quantitative RT-PCR, that the expression of the lactate dehydrogenase (LDH) A, B, and C enzymes, 
which catalyze the conversion of the final product of glycolysis pyruvate to lactate, was down-regulated in 
SCCs compared to FCCs (Fig EV4C). Conversely, unlike FCCs, SCCs were sensitive to OxPhos inhibition, as 
demonstrated by a significant increase in apoptotic cell death after treatment with rotenone or metformin, which 
are pharmacological inhibitors of the mitochondrial ETC complex I (Fig 4C-D, Fig EV4D-E).  
We next set to validate the metabolic differences between SCCs and FCCs in vivo. For in vivo glucose 
restriction, we implemented a custom high fat/low carbohydrate dietary regimen supplemented with a 
specialized fat source composed of medium-chain triglycerides (sHFLC), as previously reported (Martuscello et 
al., 2016). Subjecting animals bearing orthotopic xenotransplants of GBM patient-derived L1 SCCs or FCCs to 
this sHFLC diet significantly improved the survival of FCC-implanted, but not SCC-implanted, animals (Fig 4E-
F), indicating that SCC-derived tumors are insensitive to glucose restriction (Fig 4F).  
Based on our in vitro data showing SCCs’ heightened sensitivity to mitochondrial inhibition, we then 
treated SCC and FCC-implanted animals with rotenone. Compared with the vehicle-treated group, SCC-
implanted animals that were treated with rotenone showed a significant increase in survival (Fig 4F) while 
animals implanted with FCCs did not gain any survival benefit from the same treatment (Fig 4E).  
Together, our in vitro and in vivo data indicated that FCCs mostly utilize aerobic glycolysis and SCCs 
mitochondrial OxPhos for their survival and proliferation. To demonstrate the overall effect of the metabolic 
interventions on tumor growth, animals were also implanted with total population and treated with sHFLC or 
rotenone (Fig 4G). Inhibiting glycolysis significantly improved the survival of the animals. We observed a 
trending increased in survival with rotenone treatment however significance was not achieved. For both 
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treatments, no long-term survivors were observed. This further supports the existence of tumor heterogeneity 
and suggest metabolic plasticity as an escaping mechanism to the applied treatments. We hypothesized that 
the combinatorial inhibition of glycolysis and mitochondrial OxPhos would have a greater effect on GBM cell 
proliferation than either treatment alone by impeding metabolic adaptation and through the targeting of both the 
SCC and FCC phenotypes. Thus, we cultured GBM cells in normal or glucose-restricted conditions and in the 
presence or absence of rotenone or metformin. Glucose concentrations were maintained stable over time to 
prevent glucose supply exhaustion, especially in the rapidly growing FCC cultures. We confirmed a synergistic 
effect between glucose deprivation and mitochondria inhibition (Fig 4H-I, Fig EV4D-E). Using the generalized 
linear models (GLM, see methods), we found that inhibiting mitochondria with metformin or rotenone increased 
the overall effect of glucose deprivation by 36% and 47%, respectively. These results demonstrate that a 
functional metabolic dichotomy exists in GBM and support the presence of cells in GBM capable of switching 
from mitochondrial OxPhos to glycolysis (e.g. SCCs) and that targeting mitochondria sensitize cells to 
glycolysis inhibition. 
 
Lipid metabolite levels are increased in SCCs 
In order to investigate the metabolic pathways fueling mitochondrial OxPhos in SCCs, we performed a 
comprehensive metabolic profiling of SCCs and FCCs isolated from L0, L1, and L2 GBM cell lines cultured in 
nutrient-replete conditions using ultra-high performance liquid chromatography coupled with high resolution 
quantitation mass spectrometry (UHPLC/HRQMS). Multivariate principal component analysis (PCA) and partial 
least squares-discriminant analysis (PLS-DA) of metabolite profiles showed a segregation between FCCs and 
SCCs (Fig 5A). Pathway analysis of the metabolites that were up-regulated by at least two-fold in the SCCs 
consistently showed elevated metabolic intermediates specifically involved in lipid metabolism pathways. 
Interestingly, more than 60% of these lipid metabolites were unsaturated (Fig 5B; see Fig EV5 for the full list of 
pathways; see Table EV6 for the full list of identified metabolites).  
 
Lipid droplets constitute a form of energy storage in SCCs  
Next, we examined whether/how these increased lipid intermediates might be stored in GBM SCCs. Fatty 
acids and their saturation status have been correlated with cancer stemness (Li, Condello et al., 2017, Noto, 
De Vitis et al., 2017, Tirinato, Liberale et al., 2015), and the increased uptake of unsaturated fatty acids in 
cancer cells promotes the formation of triglyceride-enriched lipid droplets, representing an efficient way of 
storing energy (Mei, Ni et al., 2011). To compare lipid droplet amounts between SCCs and FCCs, we used a 
lipid-specific probe (LipidTox) that accumulates in intracellular lipid droplets. We observed consistent LipidTox 
staining in SCCs and a marked increase in LipidTox content in SCCs when compared to FCCs using flow 
cytometry analysis (Fig 5C-D and	Fig EV6A).  
We then quantified the amount of lipid droplets in response to glucose deprivation in order to assess 
whether these lipid droplets are utilized by SCCs or FCCs as a source of energy. We found a significant 
decrease in lipid droplet content in SCCs when these cells were cultured in low glucose conditions, whereas no 
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change was observed in FCCs (Fig 5E). These data suggest that lipid droplets represent a form of energy 
storage that can be used by SCCs in response to metabolic stress.  
We next investigated how those stored lipids might be catabolized by SCCs for energy production. Lipid 
droplets can be sequestered in autophagosomes that fuse with lysosomes following nutrient deprivation, 
leading to the breakdown of lipid droplet components by lysosomal enzymes in order to generate energy and 
meet the cells’ metabolic demands (Singh, Kaushik et al., 2009) (Dong & Czaja, 2011, Velazquez & Graef, 
2016). Interestingly, gene set enrichment analysis (GSEA) from RNA-sequencing (RNA-seq) data across the 
L0, L1, and L2 GBM cell lines revealed an elevated expression of autophagosome-lysosome genes in SCCs 
compared to FCCs (Fig 5F, Fig EV6B-C, and Table EV6) for the full list of genes defining the autophagosome-
lysosome pathway). We then set to confirm the presence of autophagosomes and lysosomes in SCCs using 
quantitative flow cytometry analysis and found a five-fold increase in the amount of autophagosomes, which 
were labeled with microtubule-associated protein light chain 3 (LC3B), in SCCs compared to FCCs (Fig 5G-H 
and Fig EV6D). In addition, immunofluorescence staining for lysosomal membrane-associated protein 2 
(LAMP2) revealed a rich network of lysosomes surrounding lipid droplets in SCCs (Fig 5I), and flow cytometry 
analysis showed increased LAMP2 expression in SCCs when compared to FCCs (Fig 5J and Fig EV6E). 
Together, our observations suggest that SCCs may engage in autophagy mechanisms to metabolize stored 
lipid, particularly in response to metabolic stress.  
 
Fatty acid transport is facilitated in SCCs  
In order to investigate the mechanisms that might contribute to the increased lipid content observed in SCCs, 
we next compared the rate of lipid uptake/transport in SCCs and FCCs. To assess basal fatty acid uptake 
activities, we performed time-course and dose-response studies for the three primary GBM L0, L1, and L2 cell 
lines using a fluorescently labeled fatty acid (C16-BODIPY). C16-BODIPY uptake was progressively stimulated 
with increasing exposure time, with significantly higher incorporation in SCCs than FCCs (Fig 6A). The 
increase in lipid analog absorption was also dose-dependent and significantly higher in SCCs than FCCs, by 
approximately 85% (Fig 6B). This increased fatty acid uptake in SCCs compared to FCCs is consistent with 
the SCCs’ elevated lipid metabolic intermediate content which we found using UHPLC/HRQMS and LipidTox 
analyses.  
 
SCCs’ resistance to metabolic stress is driven by FABP7-dependent exogenous fatty acid uptake  
To identify potential candidates regulating fatty acid uptake in SCCs, we performed gene set enrichment 
analyses of a lipid metabolism gene signature (Table EV8 for gene set description) obtained from RNA 
sequencing comparing the gene expression of SCCs and FCCs isolated from L0, L1 and L2 GBM primary cell 
lines (Fig 7A). The results showed an enrichment of lipid metabolism pathways in SCCs, and the significant 
over-expression of several fatty acid transporters was validated by qRT-PCR (Fig 7B). The results of this 
screen prompted us to focus on FABP7, which is expressed mostly by glial cells in normal brain tissue (Fig 
EV7A) and is up-regulated in glioma (Fig EV7B) (Uhlen, Fagerberg et al., 2015). FABP7 is a radial glial marker 
	 11	
enriched in glioma stem cells and associated with tumor invasiveness and poor prognosis in GBM, and a key 
protein involved in exogenous fatty acid uptake into cells and intracellular trafficking and storage (Bensaad, 
Favaro et al., 2014, De Rosa, Pellegatta et al., 2012, Liang, Bollen et al., 2006, Morihiro, Yasumoto et al., 
2013). Moreover, siRNA knockdown of FABP7 expression significantly reduced cell proliferation and migration 
(De Rosa et al., 2012). Using the Bittner dataset (Rhodes, Yu et al., 2004), we compared the expression levels 
of the FABP7 gene in cell lines derived from multiple advanced cancers. We found that FABP7 expression is 
significantly elevated in brain tumor cell lines compared to breast, colorectal, lung, ovarian, and pancreatic 
cancer cell lines (Fig 7C). In addition, using the Bredel dataset (Bredel, Bredel et al., 2005), we confirmed that 
FABP7 is elevated in GBM versus non-neoplastic brain tissues (Fig 7D). Oncomine analysis of the Shai 
dataset also revealed higher expression of FABP7 in GBM compared to lower-grade astrocytomas (Fig 7E). 
Furthermore, we interrogated the TCGA and Freij-affy-human-91666 datasets and found that higher FABP7 
expression correlated with poorer patient prognosis (Fig 7F-G). These data suggest that FABP7 expression 
carries important prognostic information about patient survival. Interestingly, and in agreement with our qRT-
PCR data, we found increased FABP7 in SCCs compared to FCCs by immunofluorescence (Fig 7H) and flow 
cytometry (Fig 7I). To further link FABP7 expression to the SCC phenotype, we identified all genes that are 
positively correlated with FABP7 using the GlioVis data portal. Gene set enrichment analysis was then 
performed to compare the expression levels of FABP7-correlated genes between the SCCs and FCCs isolated 
from L0, L1 and L2 (Supplemental Fig 7C, Table EV10). The results of this analysis support that FABP7 and 
positively correlated gene signatures are overexpressed in SCCs. Additionally, publicly available single cell 
RNA sequencing analyses (Venteicher et. al. 2017) also confirmed the over-expression of FABP7 in the slow-
cycling cells defined based on the expression of cell cycle genes as described in Tirosh et. al. 2016 (Table 
EV11).  
We next investigated the functional roles of FABP7 and FABP3, the level of which was also increased 
in SCCs compared to FCCs. The uptake of fluorescently labeled fatty acid C16-BODIPY was significantly 
decreased after treatment with pharmacological inhibitors of FABP7 (SB-FI-26) (Kaczocha, Rebecchi et al., 
2014) (Fig 7J) and FABP3 (BMS309403) (Fig EV7D) in SCCs, but not in FCCs, suggesting that these fatty 
acid transporters are essential for lipid uptake, and potentially storage, in SCCs. We then examined whether 
fatty acid uptake inhibition was associated with an altered ability of GBM cells to adapt and survive in glucose-
restricted conditions. Confirming the results described in figures 4A-B, reduced glucose levels did not 
negatively affect the growth of SCCs, but significantly decreased the proliferation of FCCs (Fig 7K). However, 
blockade of FABP7 sensitized SCCs to lower glucose levels. After combining lower glucose conditions and 
FABP7 inhibition, SCC viability was significantly reduced to a level comparable to FCCs when cultured in lower 
glucose conditions alone. The combination of FABP7 inhibition and decreased glucose levels did not result in 
any additional growth inhibitory effect on FCCs. Moreover, CRISPR/Cas 9-mediated knockout FABP7 
significantly reduced lipid uptake activity (Fig 7L) and increased the sensitivity of SCCs to pharmacological 
inhibition of glycolysis with 2-DG (Fig 7M-N). Together, these results demonstrate the central role of FABP7 for 
SCCs metabolic robustness. 
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We then tested to effect of FABP7 inhibition on the migration of SCCs. These experiments revealed 
that FABP7 inhibition caused a significant decrease of cell migration of the total population and SCCs when 
treated with FABP7i concentrations ranging from 5 nM to 10 µM (Fig EV8A). In vivo inhibition of FABP7 also 
resulted in the decreased of cell invasion (Fig EV8B). 
Finally, we tested the effects of FABP7 inhibition, alone or in combination with 2-DG in xenotransplants 
of three different GBM lines (Fig 7O-Q, Fig EV8C-D). Combinatorial treatment showed a synergistic effect in 
L2 (Fig 7O). Because the results were less robust for L0 and L1 (Fig EV8C-D) we employed the Cox frailty 
model fit to estimate predicted survival curves for our experimental treatment groups including all three GBM 
cell lines. The mortality hazard ratio (HR) of the group treated with 2-DG alone did not differ significantly from 
the control group’s (Fig 7M, HR = 0.84, P = 0.32). Both of the groups treated with FABP7i had significantly 
lower mortality hazards than the control group, with the combinatorial treatment exhibiting the greatest 
significance (FABP7i only: HR = 0.43, P = 0.032; FABP7i + 2DG: HR = 0.28, P = 0.002) (Fig 7P). The average 
(main) effect HR for 2-DG did not differ from 1 (HR = 0.74, P = 0.278), while the average effect HR for FABP7i 
was significantly less than 1 (Fig 7Q, HR = 0.38, P = 0.001). Therefore, survival was significantly improved 
when tumors were treated with FABP7i, whether alone or in combination with 2-DG, with the largest significant 
effect occurring following the combined treatment. By contrast, survival was not improved after 2-DG treatment 
alone. These results demonstrate that successful targeting of SCCs via FABP7 inhibition can improve survival.  
Together, our results show that blocking lipid metabolism through fatty acid transport inhibition negates 
the ability of SCCs to survive metabolic stresses, such as glucose restriction.  
 
Discussion 
The Warburg effect has been widely described in GBM and other tumor types. Here, we show that GBMs are 
metabolically heterogeneous and contain FCCs that rely on aerobic glycolysis and SCCs that depend on 
mitochondrial OxPhos for their survival and proliferation. Furthermore, compared to FCCs, SCCs contain 
increased levels of metabolites and components that are involved in lipid metabolism, storage, and transport 
and are also found over-expressed in recurrent GBM tumors. These properties provide SCCs with a survival 
advantage when these cells are exposed to metabolic stresses such as glucose deprivation or glycolysis 
inhibition. We show that the resistance of SCCs to glucose deprivation or glycolysis inhibition can be prevented 
by blocking fatty acid uptake, through the pharmacological inhibition or genomic deletion of the fatty acid 
transporter FABP7, in vitro and in vivo. Importantly, SCCs show increased chemotherapy resistance and 
migration/invasion compared to the rest of the tumor cell population, further suggesting their central role in 
tumor recurrence.  
Our data show that SCCs possess greater migration and invasion capabilities as well as higher 
resistance to TMZ than FCCs. Previous studies have reported that an EMT-like process positively correlates 
tumor cell invasion and chemoresistance (Depner et al., 2016, Qi et al., 2012, Siebzehnrubl et al., 2013) and 
that quiescent GBM cells display heightened chemoresistance (Campos et al., 2014, Chen et al., 2012). In 
addition, we have found that the knockdown or overexpression of the EMT transcription factor ZEB1 affects 
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GBM cell proliferation, with ZEB1 overexpression reducing tumor cell proliferation and enhancing invasion 
(Siebzehnrubl et al., 2013). Here, our results show that GBM SCCs display increased expression of ZEB1 and 
greater resistance to chemotherapy, higher migration and invasion capabilities than FCCs, in vitro and in vivo, 
and that ZEB1 knockdown significantly reduces SCC invasion. Together, these findings suggest a positive 
correlation between tumor cells’ slow proliferation rate, ZEB1 expression, invasion, and chemoresistance.  
 An increasing number of studies have been exploring tumor metabolism as a targetable vulnerability 
specific to treatment-resistant, tumor-propagating cells. Recently, metabolic heterogeneity has been described 
in animal models of GBM (Conrad, Fueyo et al., 2014, Marin-Valencia et al., 2012, Vlashi, Lagadec et al., 
2011) and other tumors, e.g., melanoma, lymphoma, leukemia, and lung and pancreatic cancer (Caro, Kishan 
et al., 2012, Hensley, Faubert et al., 2016, Lagadinou, Sach et al., 2013, Roesch, Vultur et al., 2013, Viale, 
Pettazzoni et al., 2014).Using isotopic labeling, Marin-Valencia and colleagues have demonstrated that 
functional mitochondrial OxPhos activity is maintained in GBMs (Marin-Valencia et al., 2012), suggesting that 
those tumors might not exclusively rely on aerobic glycolysis, as originally described. SCCs have been shown 
to display specific metabolic pathways geared towards the utilization of mitochondrial respiration in other 
cancer types (Caro et al., 2012, Lagadinou et al., 2013, Roesch et al., 2013, Viale et al., 2014). 
Complementing those studies, our results demonstrate increased mitochondria and OxPhos activities in the 
GBM SCC population. Interestingly, our bioinformatics analyses reveal an increased expression of genes 
regulating mitochondrial OxPhos in recurrent GBMs compared to primary tumors, and we have found an 
increased expression of mitochondria-specific genes in SCCs that are similar to those found in recurrent 
tumors. Chemoresistance has also been positively correlated with increased mitochondrial activity in GBM 
(Oliva, Moellering et al., 2011, Wolf, 2014). Thus, our findings suggest that chemoresistant SCCs may be a 
major driver of GBM recurrence, and further studies will be needed to fully understand the mechanisms 
underlying the role of SCCs in recurrent tumors. 
We have recently reported that treating GBM-bearing animals with a custom high fat/low carbohydrate 
diet significantly improved animal survival in a patient-derived orthotopic xenograft model; however, tumor 
progression still persisted (Martuscello et al., 2016). Based on the metabolic characterization of SCCs 
described here, we hypothesized that SCCs might drive disease progression under glucose restrictive 
conditions by bypassing glycolysis and utilizing mitochondrial OxPhos. We have found that SCCs are sensitive 
to the pharmacological inhibition of the electron transport chain/ mitochondrial OxPhos but resistant to glucose 
deprivation or glycolysis inhibition with 2-DG. These treatments have opposite effects on the FCC population. 
Importantly, targeting both OxPhos and glycolytic pathways in vitro or in vivo has a synergistic inhibitory effect 
on the total GBM cell population’s viability, which is likely due to the restriction of metabolic plasticity of the 
cells and prevention of metabolic compensatory mechanisms. Our results demonstrate the existence of a 
fundamental metabolic dichotomy between SCCs and FCCs in GBM. Whether these metabolic divergences 
are the cause or effect for the differential growth patterns between SCCs and FCCs still remains to be 
determined. In addition, the detailed mechanisms underlying the metabolic specificities of these two cell 
populations need to be further explored.  
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Alterations in lipid metabolism have been described in various cancers, including GBM (Bensaad et al., 
2014); however, the role of lipids in tumor initiation, maintenance, as well as migration and treatment sensitivity 
is not fully understood. Here, we find that SCCs exhibit an up-regulation of lipid-related metabolic genes. 
Interestingly, our analyses show that recurrent GBM tumors display an increased expression of the same lipid 
metabolism pathways when compared with primary GBM tumors, further suggesting the role of SCCs in tumor 
relapse. Intriguingly, a similar link between stemness and metabolic specificities exists in normal neural and 
GBM tissue. Both stem-like GBM SCCs and adult mammalian neural stem cells lack glucose dependency and 
are able to oxidize diverse sources of fuel, including fatty acids (Stoll, Makin et al., 2015). In contrast, similarly 
to transit-amplifying neural progenitor cells, GBM FCCs display lower requirements for OxPhos metabolism 
and depend on glycolysis (Candelario, Shuttleworth et al., 2013, Li, Candelario et al., 2014, Stoll et al., 2015). 
Together, our findings suggest that slow-cycling phenotype, lipid metabolism, treatment resistance and tumor 
recurrence might be closely connected. 
 Furthermore, a recent report by Lin et. al. has demonstrated that mitochondrial OxPhos activity is 
dependent on fatty acid oxidation to support the proliferation of GBM cells cultured in serum-free conditions 
(Lin et al., 2017). Other studies have shown that GBM cells store fatty acids as lipid droplets in response to 
metabolic stresses such as hypoxia and use a FABP-dependent mechanism to oxidize fatty acids for energy 
production and adapt to environmental disruptions (Bensaad et al., 2014). Our results validate these findings 
and further demonstrate that the SCC population is specifically characterized by a higher expression of FABPs 
and greater lipid droplet amounts when SCCs are grown in normoxic or nutrient-replete conditions. We 
propose that SCCs accumulate energy reserves as lipid droplets in these conditions through a mechanism 
controlled by FABP-associated pathways, as fatty acid transport is prevented by the inhibition of these 
pathways. In addition, compared to FCCs, our study show increased SCC survival and preferential utilization of 
lipids droplets in response to glucose restriction or glycolysis inhibition. Moreover, the metabolic resistance of 
SCCs to glucose deprivation or glycolysis inhibition can be prevented by the pharmacological inhibition or 
genomic deletion using CRISPR/Cas9 of FABP7, both of which block the uptake of fatty acids upstream of 
intracellular lipid metabolic pathways, in vitro and in vivo. Importantly, we have found that FABP7 inhibition 
leads to overall increased survival, whether alone or in combination with glycolysis inhibition, suggesting that 
FABP7 is central to lipid metabolism in SCCs and that targeting FABP7-related metabolic pathways is a viable 
therapeutic strategy. At high glucose concentrations, FABP7 inhibition did not prevent cell survival and 
proliferation, which suggests that the fatty acids can be synthesized for metabolism and energy production 
from other nutrients, including glucose or glutamine. We also found, in SCCs compared to FCCs, a significantly 
increased presence of autophagosomes and lysosomes and expression of associated pathways, which are 
known to mediate catabolic pathways that provide energy to cells in response to decreased nutrient 
availabilities. Future studies will be needed to determine whether lipid reserve utilization is dependent on those 
autophagosomal and lysosomal pathways.  
 Chemotherapeutic agents, such as TMZ, induce oxidative stress by increasing ROS (Chandra, Samali 
et al., 2000, Zhang, Wang et al., 2010) as well as FABP expression (Bensaad et al., 2014), lipid droplet content 
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(Bensaad et al., 2014), and anti-oxidant properties through the glutathione pathway (Landriscina, Maddalena et 
al., 2009), all of which have all been linked to TMZ resistance (Oliva et al., 2011). The increased levels of 
glutathione-related metabolites observed in GBM SCCs suggest that these cells’ increased anti-oxidant 
activity, which could also involve the FABP/lipid droplet axis, might cause their chemoresistance (Bensaad et 
al., 2014). Additionally, as autophagy has been linked to resistance to chemotherapy (Belounis, Nyalendo et 
al., 2016, Guo & White, 2017, White, Mehnert et al., 2015), including TMZ (Yan, Xu et al., 2016), the 
autophagosomes that we observed in SCCs may also contribute to TMZ resistance. Therefore, autophagy 
might represent a pathway that could be therapeutically targeted to sensitize SCCs to TMZ.  
 We propose that the specific characteristics of GBM SCCs play a critical role in their tolerance to 
chemotherapy and that interference with lipid metabolism in SCCs may be exploited to target those cells and 
overcome tumor chemoresistance. Moreover, peptidome analysis of GBM has identified FABP7 as one of the 
top ten GBM-specific, HLA molecule-associated peptide with high immunogenic properties (Dutoit, Herold-
Mende et al., 2012), a characteristic that could be exploited for immunotherapeutic targeting of SCCs. 
Communication between cancer cells and their microenvironment, including immune cells, has been 
suggested, and the implication of fatty acids as regulators of this crosstalk is starting to gain recognition 
(Beloribi-Djefaflia, Vasseur et al., 2016). Further investigations are needed to fully understand their roles in this 
intercellular communication process, especially in SCCs.  
SCCs have been garnering increasing attention in the cancer research field, and a better understanding 
of their specific features and vulnerabilities holds great therapeutic promise, potentially enabling the 
development of novel targeted treatments to overcome tumor relapse (Campos et al., 2014, Caro et al., 2012, 
Dembinski & Krauss, 2009, Gao et al., 2010, Graham et al., 2002, Lagadinou et al., 2013, Moore et al., 2012, 
Oshimori et al., 2015, Pece et al., 2010, Roesch et al., 2010, Roesch et al., 2013, Viale et al., 2014, Zeuner et 
al., 2014). Our characterization of the nature of GBM’s metabolic heterogeneity might have a significant impact 
on the improvement of metabolic therapies, particularly those targeting the Warburg effect. In addition, our 
study provides a new basis for studying the link between GBM chemoresistance and tumor cell metabolism, 
especially as it relates to lipid metabolic pathways in SCCs. Further identification of the lipid metabolites that 
are present in GBM SCCs may reveal a unique metabolic marker signature for treatment-resistant/tumor-
initiating cell populations, as well as potential new targets for cancer stem cell-specific therapies. 
 
Materials and Methods 
Cell culture 
The primary cell lines used in this study, Line 0 (L0), Line 1 (L1) and Line 2 (L2) (Deleyrolle et al., 2011, 
Siebzehnrubl et al., 2013), were isolated from human GBM tumors and cultured as previously described and 
approved by Institutional committee (IRB) (Deleyrolle et al., 2011, Hoang-Minh, Deleyrolle et al., 2016, 
Sarkisian, Siebzehnrubl et al., 2014, Siebzehnrubl et al., 2013, Siebzehnrubl, Vedam-Mai et al., 2011). 
Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the 
WMA Declaration of Helsinki and Department of Health and Human Services Belmont Report. The lines were 
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authenticated using STR analysis (University of Arizona Genetics Core). Cells were grown as floating spheres 
and maintained in Neurocult NS-A medium (StemCell Technologies) in the presence of 20 ng/mL human EGF. 
When the spheres reached approximately 150 μm in diameter, they were enzymatically dissociated by 
digestion with Accumax (Innovative Cell Technologies, Inc.) for 10 min at 37°C. Cells were then washed, 
counted using Trypan blue to exclude dead cells, and re-plated in fresh complete medium. To generate TMZ-
resistant cells, cells were initially treated with 500 µM TMZ for one passage and then continuously exposed to 
20 µM TMZ. 
 
Isolation of fast- and slow-cycling cells 
Populations of slow-cycling cells (SCCs) and fast-cycling cells (FCCs) were identified and isolated primary 
human glioblastoma cell lines based on their capacity to retain CellTrace dyes (Carboxyfluorescein 
succinimidyl ester-CFSE or Cell Trace Violet-CTV, Invitrogen), as described previously (Deleyrolle et al., 
2011), and grouped as CFSE/Violethigh- top 10% and CFSE/Violetlow- bottom 10%. For the experiments 
presented in figure 1D-E, FCCs were isolated as CFSElow- bottom 85% (Deleyrolle et al., 2011). Our gating 
strategy allows for the isolation of functional and phenotypic extremes with similar size population, 
homogenizing for sorting time and hence overcoming the issue of fluorescence-activated cell sorting (FACS)-
related metabolic stress. Both SCC and FCC populations are able to expand in vitro and in vivo, demonstrating 
their viability and expansion capacities (Deleyrolle et al., 2011). Although this strategy does not capture the full 
spectrum of cellular population contained in GBM, it provides a relevant paradigm to compare defined cellular 
components or states with distinct proliferation properties. Proliferation was assessed based on CellTrace 
fluorescence intensity decay rate over time measured by flow cytometry and identified 6-8 days post labeling. 
This process enabled the separation of rapidly proliferating (FCCs) and slowly proliferating (SCCs) cell 
fractions (top and bottom 10%) based on CellTrace fluorescence intensity, which is proportional to dye dilution. 
We used these most extreme fractions of the proliferation spectrum in order to ensure clear and distinct 
separation of FCCs and SCCs based on cell cycle kinetics. All experiments were performed immediately after 
FAC-sorting of those SCC and FCC populations. 
 
Scratch assay 
Sorted SCCs and FCCs were plated as described previously (Siebzehnrubl et al., 2013) at 2 million cells per 
well of a six-well plate pre-coated with poly-D-lysine and laminin, in medium containing 1% fetal bovine serum. 
Twenty-four hours after plating, a scratch was made with a 200-µL pipette tip. Cells were imaged at the time of 
lesion, as well as 24 hours later, and the distance traveled by the most migratory cells was recorded. 
 
Migration Assay  
For quantification of cell migration, tumor spheres were plated onto a laminin/poly-D-lysine coated surface at 
low density and in the presence of growth factors, FABP7 inhibitor (SB-FI-26), or DMSO as a solvent control. 
Images were taken from the same spheres 2 hours and 24 hours after plating with a Leica DM IL microscope 
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equipped with a DFC3000G camera and Leica application suite X software. The greatest distance of 
outgrowing cells was measured using ImageJ, and migration distance was calculated as the difference 
between the two time points. Only spheres with a diameter greater than 50 µm, 2 hours after plating, were 
used to measure migration distance.  
 
In vivo invasion quantification 
To quantify the effects of ZEB1 on the invasion of SCC, GBM cells were stably transfected with shZEB1 or 
shControl constructs as described (Siebzehnrubl et al., 2013). After selection, transfected cells were loaded 
with CFSE and separated into SCC and FCC fractions, and each intracranially injected into 5 SCID mice as 
described (Siebzehnrubl et al., 2013). Mice were transcardially perfused 12 weeks after implantation, their 
brains harvested and post-fixed in 4% formalin overnight. Brains were sectioned and stained and analyzed 
using the Invasion Index as described (Siebzehnrubl et al., 2013). 
To assess the intrinsic invasion capacity of SCC and FCC populations, sorted SCC/FCC populations 
were allowed to recover for 24 hours in culture and then transduced with lentiviral vectors encoding for 
humanized eGFP (SCCs) or humanized RFP (FCCs) (both kind gift of Dr Lung-Ji Chang, University of Florida). 
In both cases, the transduction efficiency was greater than 95%. Cells were allowed to expand and then 
dissociated into single cells and mixed at a ratio of 1:1. 105 cells of this mixture were intracranially implanted 
into SCID mice. Mice were transcardially perfused 6 weeks after implantation and their brains harvested and 
post-fixed in 4% formalin overnight. Brains were sucrose-protected, frozen, and sectioned. Sections were 
counterstained with Hoechst 33342, mounted onto slides, and imaged for GFP and RFP using an Olympus 
BX-81 DSU spinning-disc confocal microscope and Slidebook software. 
 
Cell viability/proliferation assays 
The Methyltetrazolium bromide (MTT) assay was used as an indicator of cell viability and performed as 
described (Siebzehnrubl et al., 2013). Briefly, 2000-5000 cells were plated per well in 96-well plates, in medium 
containing 1% fetal bovine serum. The cell populations were treated with TMZ one day after plating and 
analyzed with MTT assay 96 hours later. Bar graphs were derived from individual concentration 
measurements, which were compared to the appropriate controls.  
Propidium iodide incorporation and expression of cleaved caspase 3 were used to compare the effects 
of glucose restriction and/or mitochondrial function inhibition (by rotenone or metformin treatment). Briefly, cells 
were labeled with CellTrace dye and grown in complete medium for 5-7 days before being placed in high 
glucose (HG; > 500 mg/dL) or physiological glucose conditions (PG; 90-110 mg/dL) and/or treated with 
rotenone (0.5-1 µM) or metformin (10-20 mM) for 24 hours. Media glucose concentrations were monitored 
daily and maintained constant throughout the experiments by adding glucose to the cell cultures as needed, 
which prevented the glucose supply exhaustion that might have occurred due to FCCs’ higher division rate. 
Propidium iodide and cleaved caspase 3 staining were quantified using flow cytometry. The effects of 
restricting glucose along with mitochondrial targeting using rotenone or metformin were investigated using the 
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CyquantTM assay. Cells were plated at 60,000 cells per well in 96-well plates and exposed to the treatments 
alone or in combination (physiological glucose, 0.5 µM rotenone, and 10 mM metformin). Cyquant binding dye 
was added to each well and incubated for 30 min at 37°C before being quantified using BiotekTM CytationTM 3 
Cell Imaging Multi-Mode Reader.  
 
Assessment of mitochondrial function 
Cells were seeded at a density of 30,000 cells in 80 µL medium per well in XF96-well microplates (Seahorse 
Bioscience) (n = 10) pre-coated with 22.4 µg/mL Cell-Tak Adhesive (Corning). SCCs and FCCs were 
incubated for 24 hours in standard growth medium in a humidified incubator at 37°C with 5% CO2. After 24 
hours, the standard medium was exchanged for XF Base Medium pH 7.4 (Seahorse Bioscience) 
supplemented with 25 mM glucose, 2 mM L-glutamine, and 1 mM sodium pyruvate. The cells were then 
incubated for 1 hour at 37°C without CO2. OCRs were measured using the XF Cell Mito Stress Assay 
(Seahorse Bioscience) and prior to and following additions of: 1) ATP synthase inhibitor (1 µM oligomycin), 2) 
uncoupler (1 µM carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)), and 3) Complex I/II inhibitors 
(0.5 µM Rotenone/Antimycin A). Data were analyzed using Wave Desktop Software (Seahorse Bioscience), 
following the manufacturer’s instructions, and normalized to 
protein levels. 
 
ATP level measurement 
ATP levels were measured using the luciferase-based ATP-lite assay (Perkin Elmer) as per the 
manufacturer’s instructions. Briefly, 10,000 SCCs or FCCs were seeded per well (n = 10) of a black-walled 
96-well tissue culture plate. Luminescence (indicative of intracellular ATP levels) was measured using a 
Spectra Max i3x microplate reader (Molecular Devices) and normalized to protein levels for each well. 
 
Electron Microscopy 
SCCs and FCCs were separated by FACS before being fixed with 2.5% glutaraldehyde in 0.1 M 
cacodylate buffer (pH 7.4) overnight and washed with 0.1M cacodylate buffer again. Cells were then post- 
fixed in 1% osmium tetroxide for 1 hour before additional buffer washes. Cells were dehydrated through an 
ethanol series followed by 3 additional 100% ethanol. Subsequently, cells were infiltrated with a mixture of 
100% ethanol and Eponate 12 resin (Ted Pella Inc., Redding, CA) and then pure Eponate 12 resin overnight. 
Cells were embedded in Eppendorf tubes and then placed in a 60 C oven for polymerization. Ultrathin 70-80 
nm- thick sections were cut on a Leica UltraCut microtome. Sections were then stained with 5% uranyl acetate 
for 15 minutes followed by 2% lead citrate for 15 minutes. Mitochondria were imaged with a JEOL JEM-1400 
transmission electron microscope (Tokyo, Japan) equipped with a Gatan US1000 CCD camera (Pleasanton, 
CA). The data described here was gathered on the JEOL JEM-1400 120kV TEM supported by a National 
Institutes of Health Grant S10 RR025679. 
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Generation and maintenance of FABP7-depleted cell lines 
To generate FABP7-depleted patient-derived GBM cell lines, we screened and identified CRISPR/Cas9-
encoding plasmids containing a GFP reporter gene that could target human FABP7 [Sigma-Aldrich; 
CRISPR/Cas-GFP vector (pU6-gRNA-CMV-Cas9:2a:GFP); primer pair ID: HS0000240647; FABP7 gRNA 
target sequence: CTTGACTGATAATTACCGT]. For transfection experiments, GBM cells were grown on 10-
cm2 plates and transfected (Lipofectamine 2000; Life Technologies) at 60% to 70% confluence with 0.5 μg/ml 
of the CRISPR/Cas9-encoding plasmid DNA. Twenty-four to 48 hours after transfection, GFP-positive cells 
were sorted as individual clones into 96-well plates containing 250 μl of complete medium supplemented with 
hEGF and bFGF using a BD FACS Aria II Cell Sorter (BD Biosciences, San Jose, CA), excluding cell debris 
and dead cells from the analysis by forward- and side-scatter gating and PI exclusion. Stable cell lines from 
each GFP-positive clone were then expanded and screened for the presence of FABP7 by 
immunofluorescence microscopy analysis as well as flow cytometry. GFP-positive clones with undetectable 
FABP7 levels were designated CRISPR FABP7 (crFABP7, L1 clone H7). For immunostaining, once cells 
formed spheres greater than 100 μm in diameter in each well, the spheres were mechanically dissociated, 
replated, and expanded into Labtek chambered slides in 5% FBS-supplemented complete medium. After 2 to 3 
days, cells were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (4% PFA) for 
immunohistochemical analysis as described below.   
 
Animal experiments 
Adult male NOD-SCID mice (7-15-week-old) were used for in vivo tumor implants following NIH and 
institutional (IACUC) guidelines and regulations for animal care and handling. The mice colonies were 
maintained at the University of Florida’s animal facility. Animals were randomized to cages following 
implantation. For in vivo tumor invasion assay, FAC-sorted cells were intracranially implanted as previously 
described(Deleyrolle et al., 2011, Siebzehnrubl et al., 2013) and invasion assay was performed 10 weeks post 
implant. For in vivo TMZ treatment, animals were implanted with 100,000 cells immediately after cell sorting. 
Tumor-bearing animals were intraperitoneally treated with 5 injections of 20 mg/kg TMZ over 5 days at 3 
(hGBM L0) or 4 (hGBM L2) weeks post implantation. For in vivo restricted glucose and mitochondria targeting 
experiments, animals were xenografted with SCCs or FCCs and subjected to either a high carbohydrate 
control diet or a custom supplemented high fat/low carbohydrate dietary regimen (sHFLC) (Martuscello et al., 
2016). Each group received vehicle or rotenone treatment (0.5 mg/kg i.p, once a week for 6 weeks).  
 
Mass spectrometry-based metabolite screening 
CellTrace-labeled cells were cultured in gliomasphere growth conditions for 5-7 days before being separated 
into SCCs and FCCs using FACS. Upon isolation, cells were placed into 10 mM ammonium acetate for 
metabolic fingerprinting using UHPLC/HRQMS. Detected metabolites were identified based on both retention 
time and mass accuracy using major metabolite databases, including the Human Metabolome DataBase 
(HMDB), Madison Metabolomics Consortium Database (MMCD), Metlin, LIPID MAPS, and our 700 compound 
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internal library (from the Southeast Center for Integrated Metabolomics). For final identification, tandem MS 
was performed to confirm assignment. Statistical analyses were performed using JMP 11 and Metaboanalyst 
(http://www.metaboanalyst.ca), a free R-based metabolomic statistical analysis package. In addition, 
multivariate statistics including principal components analysis (PCA) and partial least squares-discriminant 
analysis (PLS-DA) were used to identify metabolites that might differentiate the cell lines or cellular subtypes. 
 
Lipid uptake 
Each cell line was labeled with CellTrace dye and grown for 5-7 days. Cells were then dissociated and treated 
with different BODIPY®FLC16 (Molecular probes) concentrations and incubation times described below. Fatty 
acids conjugated to BODIPY fluorophore undergo native-like metabolism and transport. Dose response was 
performed with 0, 0.5, 2.5, 5, 10, 25, and 50 nM BODIPY, and the time course was done at a concentration of 
5 nM for 1, 4, 5, 10, and 15 min. The cells were then washed and fixed with 4% paraformaldehyde. To 
determine the amount of fatty acid uptake, cells were analyzed by flow cytometry on a BD LSRII Flow 
Cytometer. Fatty acid transporter inhibitors SB-FI-26 (Cayman Chemicals, #14191) and BMS309403 (Millipore, 
#34310) were used to inhibit FABP7 (Kaczocha et al., 2014) and FABP3 (Furuhashi, Tuncman et al., 2007), 
respectively. 
 
Dyes and antibodies  
Dyes and primary antibodies used for flow cytometry or immunocytochemistry included CellTrace™ Violet and 
CFSE Cell Proliferation Kit (Molecular Probes), DAPI (Molecular Probes), Hoechst (Thermo Scientific), DRAQ5 
(Thermo Scientific), Propidium Iodide (Molecular Probes), LipidTox (ThermoFisher Scientific), Mitotracker 
Green and orange (Molecular Probes), MitoProbe DiIC1(5) (Molecular Probes), FABP7 (Santa Cruz 
Biotechnology, #sc-30088), FABP7 (R&D Systems, #AF3166), human Nestin (Millipore, #MAB5326), N-
cadherin (Millipore, # 04-1126), beta-catenin (Sigma, #C2206), ZEB1 (Sigma, #HPA027524) , VDAC1 (Abcam, 
#ab15895), cleaved caspase-3 (Cell Signaling Technology, #9661S), NDUFA4 (Abcam, # ab129752), ATP 
Synthase (BD Biosciences #612518), LC3 (Cell Signaling Technology, #3868S), and LAMP2 (Abcam, # 
25631) antibodies. 
 
Flow cytometry 
Six to 8 days post-CellTrace load, labeling was performed using the antibodies and dyes that are listed above 
and according to the manufacturer's protocol. Staining was quantified by flow cytometry (BD LSRII) and 
percent of immunoreactive cells or mean fluorescence intensity (MFI) were reported.  
 
Image acquisition  
Tumor invasion was measured using human-specific nestin labeling (Millipore, MAB5326). Full images of brain 
sections were obtained by multiple gray scale imaging acquired using Spot Advanced software (Spot Imaging 
Solutions), merged into full images, and inverted into black-and-white images using Photoshop CS6 (Adobe 
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Systems). Staining threshold levels were adjusted in Image J software to distinguish tumor from background, 
as previously described (Siebzehnrubl et al., 2013). Invasion index was obtained by calculating the ratio of the 
squared-perimeter distance over the area (P2/A). Dissociated tumors are associated with higher invasion 
indices compared to more spherical tumors characterized by lower invasion indices. High-power images of 
stained tissues were taken using an IX81-DSU spinning disc confocal microscope (Olympus) fitted with a 60x 
water immersion objective, and all images were captured as z-stacks (0.5 µm steps). For 3D imaging, pictures 
were acquired using a UPLSAPO 60x water objective and Hamamatsu ORCA-AG Camera. Images were 
captured as z-stacks (0.5 µm steps). All image analyses and 3D surface reconstructions utilized the 3i 
SlideBook v4.2 Software (with Deconvolution Module). Image capture settings were standardized across 
samples. 3D surface reconstruction rendering cut-off values were also standardized in the 3i SlideBook 
software. 
 
RNA sequencing and GSEA 
The autophagosome-lysosome gene set was compiled by combining the list of genes from The Human 
Lysosome Gene Database (http://lysosome.unipg.it/index.php) and the GO_Autophagosome gene set 
(http://software.broadinstitute.org/gsea/msigdb/cards/GO_AUTOPHAGOSOME.html). Enrichment of the gene 
signature was assessed using GSEA (http://www.broadinstitute.org/gsea/index.jsp), and p values were 
obtained by permuting the phenotypes (1000 permutations). To broaden the validity of the gene signature 
enrichment, additional gene sets were used based on previously published autophagosome-lysosome gene 
signatures (Perera, Stoykova et al., 2015) (Jegga, Schneider et al., 2011). The stem cell signature was derived 
from (Wong et al., 2008). GBM single cell RNA sequencing data were generated from (Venteicher et al., 2017). 
Differential expressed genes were extracted from groups by nonparametric t test (p<0.05). Gene set 
enrichment analysis was performed using Genepattern ssGSEA.  
 
Bioinformatics analysis 
Using information from the TCGA dataset (Cancer Genome Atlas Research, 2008), we analyzed the RNA 
expression of 155 primary (de novo) and 14 recurrent patients’ GBM tumors. All 20,530 identified genes were 
normalized by log2 transformation and centered by mean value. Results were presented using a volcano plot 
comparing recurrent and primary GBM gene expression using a threshold of a 2-fold change with p < 0.05 
(Mann-Whitney U-test, Subio platform) as significant difference. For pathway analyses, we used the Search 
Tool for the Retrieval of Interacting Genes/Proteins (STRING) database platform (Szklarczyk et al., 2015) 
(http://string-db.org) to identify functional networks differentially activated between primary and recurrent 
tumors. The datasets that were utilized are indicated in the text, figure legends, and on the figures. TCGA data 
were accessed at https://tcga-data.nci.nih.gov/ tcga/tcgaHome2.jsp. 
 
Quantitative RT–PCR  
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SCCs and FCCs were isolated from cell lines L0, L1, and L2 as described above. RNA was extracted using 
Trizol. After treatment with RNase-free DNase I, cells from each group were purified using the RNeasy Mini kit 
(Qiagen). RNA quantity and purity were determined using a NanoDrop ND-1000, and RNA integrity was 
assessed by determining the RNA integrity number and 28S/18S ratio using a Bioanalyzer 2100 (Agilent 
Technologies). A quantity of 500 ng of high-quality RNA (260/280 ratios slightly higher than 2.0 and 260/230 
ratios higher than 1.7) for each group was converted into cDNA using the RT2 First Strand cDNA Kit 
(SABiosciences). All qPCR reactions used the RT2 SYBR Green qPCR Master Mix (SABiosciences). Fatty acid 
metabolism gene expression was determined using the Fatty Acid Metabolism PCR Array (PAHS-007Z, 
SABiosciences), and the C100 Touch Thermal Cycler CFX96 Real-Time System (Bio-Rad) according to the 
manufacturer's protocol. FABP7 expression levels were assessed using the primers listed in Table EV 7. All 
significant changes in gene expression levels are reported in the article; the complete list of genes assayed on 
the array can be found at the manufacturer's website 
(http://www.sabioscience.com/rt_pcr_product/HTML/PAHS-007Z.html). For additional glucose metabolism 
gene analyses, LDH-A, B, and C expression levels were detected using the C100 Touch Thermal Cycler 
CFX96 Real-Time System (Bio-Rad) with Actb as control. Primers were purchased from ThermoFisher 
Scientific. The qRT–PCR primers designed for this study are listed in Table EV7. 
 
Statistics 
Values reported in the results are mean values +/- SEM, and statistical analyses were performed using 
GraphPad Prizm 6.0 (GraphPad Software). Statistical tests are indicated in the text. Comparisons between 
groups were performed appropriately using either a one-way ANOVA or a Student's t-test (95% confidence 
intervals). Groups that showed significant differences with ANOVA were further subjected to Tukey's post-hoc 
analysis. In vivo survival analyses were calculated using log-rank analyses. Flow cytometry analysis was 
performed using FlowJo software. We used generalized linear models (GLM) with log-normal errors 
(McCullagh & Nelder, 1989) to analyze the effect of experimental factors on mean responses. All experiments 
analyzed in this way involved at least 2 experimental factors. Corresponding models included design variables 
representing the main effects and interactions among factors. Survival time responses were converted to 
"pseudo-observations" that more accurately represented the contributions of observed and right-censored 
survival times to unbiased survival time mean estimates (Klein, Gerster et al., 2008). GLM models 
incorporating a robust "sandwich" estimator for the covariance matrix (equivalent to generalized estimating 
equation models) were fitted to pseudo-observation survival times. Residuals from model fits were evaluated 
graphically to assess model fit assumptions. F tests were used to test the significance of interactions and main 
effects. Means and 95% confidence intervals (CI) were estimated for various experimental conditions. Percent 
differences between means, and percent differences between the effects of experimental factors represented 
by interactions, were estimated and tested for significant difference from zero using t statistic contrasts within 
the framework of fitted models. Via repeated simulation of responses within our various experimental designs, 
we determined that we had 80% power to detect 49% to 55% percent differences between effects within 
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interactions at a 2-sided significance level of 0.05. Model-fitting and estimation was carried out using SAS 
Version 9.4 (SAS Institute, Cary NC). Data simulation and retrospective power calculations were carried out 
using R Version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). 
Study approval 
All procedures involving mice were performed according to NIH and institutional guidelines for animal care and 
handling. 
 
Data availability 
The data that support the findings of this study are available from the corresponding authors on reasonable 
request. 
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Figures and figure legends 
Figure 1: Invasiveness and chemoresistance as hallmarks of SCCs in GBM. SCCs and FCCs were 
identified and purified using the sorting paradigm described in Fig EV1A. (A) Scratch assays demonstrated a 
greater migratory potential for SCCs than for FCCs (n=6, ** p < 0.01, t-test). (B) Following murine xenografts of 
L1 or L2 patient-derived cell lines, SCCs produced invasive tumors, while FCCs produced confined masses. 
Ten weeks after implantation, SCC-derived tumors, and total population-derived tumors for L1, exhibited 
greater invasion indices than FCC-derived tumors (n=3-12, ** p < 0.001, *** p < 0.001, one-way ANOVA with 
Tukey post-test). (C) Representative fluorescence microscopy images of tumor sections derived from 
intracranial xenografts of a 1:1 ratio of lentivirally transduced green fluorescent protein (GFP)-labeled SCCs 
and red fluorescent protein (RFP)-expressing FCCs, six weeks after implantation (n=5). SCCs (in green) 
generated a network of cells infiltrating the brain parenchyma while FCCs (red) remained contained, forming 
tight masses. Images are from 2 mice out of 5. Scale bar 10 µm. (D) The invasion of tumors derived from 
orthotopic xenografts of ZEB1 knockdown SCCs was significantly lower than that of control SCC-derived 
tumors (n=6, ** p < 0.01, *** p < 0.001, t-test). (E) SCCs were significantly more resistant to TMZ in vitro using 
MTT assays (n=6-8, *** p < 0.001, one-way ANOVA with Tukey post-test). (F) In vivo TMZ treatment yielded 
no survival benefit following SCC xenograft of the most TMZ resistant GBM line, whereas TMZ treatment of 
animals xenografted with the non-SCC population resulted in significantly prolonged survival. (G) TMZ 
treatment of animals xenografted with SCCs from a more TMZ-sensitive line increased overall survival, but to a 
lesser degree than for non-SCC-implanted animals (D-E: n=5, ## p < 0.01, t-test). 
 
Figure 2: Shared metabolic gene signature between recurrent GBM and SCCs. (A) Volcano plot 
representation of the 20,530 genes that were identified in primary and recurrent human GBMs using the TCGA 
database revealed differentially expressed genes between the two groups. Gray areas denote significant 
increases or decreases in gene expression. Recurrent tumors showed a significant increase in the expression 
of genes involved in lipid metabolism, mitochondrial respiration, TCA cycle, as well as pyruvate and antioxidant 
metabolism (fold change > 2 and p < 0.05, Mann-Whitney U-test, Subio platform) These genes were then 
clustered into two signatures representing lipid metabolism and oxidative-reduction (Ox-Red) genes. (B) GSEA 
of SCC (n=3 biological replicates, L0-1-2) and FCC (n=3 biological replicates, L0-1-2) RNA-seq data sets for 
enrichment of these recurrent glioblastoma (rGBM) gene signatures. FDR, false discovery rate; NES, 
normalized enrichment score; Nom., nominal. (C) Different metabolic signatures were identified from GBM 
single cell RNA sequencing data (Venteicher et al., 2017). These results generated by Genepattern ssGSEA 
and visualized with pheatmap (Euclidean algorithm) demonstrate metabolic heterogeneity in GBM, with various 
clusters of cells demonstrating gene signatures for OxPhos and glycolysis. 
 
Figure 3: Enhanced mitochondrial activity in SCCs. (A) Fluorescence microscopy images of tumor sections 
derived from intracranial xenografts of L1 SCCs or FCCs and immunostained with the mitochondrial marker 
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MTCO2 showed a higher number of mitochondria in SCC-derived tumors. Electron microscopy analysis (B) 
and quantification (C) revealed a higher number of mitochondria per cell in SCCs than in FCCs for L0, L1, and 
L2. (D) Quantification of MitoTracker Green staining in SCCs (CTVhigh) and FCCs (CTVlow) derived from hGBM 
L0 (n=10), L1 (n=13), and L2 (n=6) consistently showed higher mitochondrial content in SCCs. (E) 
Fluorescence microscopy images of single cells labeled for VDAC1 (red), DAPI (blue), and CFSE (green). 
Scale bar, 5mm. (F) Flow cytometry quantification of VDAC1 in SCCs and FCCs showed increased VDAC1 
levels in SCCs (n=2 for all lines). Flow cytometry quantification of mitochondrial complex I (n=3 for all lines) (G) 
and complex V (L0, n=3; L1, n=3; L2, n=6) (H) revealed an increase in these mitochondrial electron transport 
chain components in SCCs when compared with FCCs. (I) Quantification of MitoTracker Orange staining 
showed significantly higher mitochondrial reactive oxygen species production in SCCs than in FCCs (L0, n=9; 
L1, n=2; L2, n=6). (J) SCC and FCC mitochondrial membrane potentials were analyzed with the MitoProbe 
DilC1 assay (L0, n=4; L1, n=2; L2, n=5). Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) was added as 
control mitochondrial membrane uncoupler. (K) Seahorse experiments were conducted to compare the 
mitochondrial function between SCC and FCC populations. The oxygen consumption rate (OCR) responses 
were quantified using the Seahorse XF Cell Mito Stress Test. The dashed lines indicate the timing of 
oligomycin (1), FCCP (2), and rotenone with antimycin A (3) injections. Basal (L) and maximal (M) oxygen 
consumption rates (OCR) as well as ATP production (N) were significantly higher in SCCs than in FCCs for L0, 
L1, and L2. * p < 0.05, ** p < 0.01, *** p < 0.001, t-test. 
Figure 4: Metabolic dichotomy in GBM. (A) SCCs and FCCs were cultured in high glucose (HG, > 500 
mg/dL) or physiological glucose (PG, 90-110 mg/dL) conditions for 24 hours. Cell death was quantified by flow 
cytometry through propidium iodide (PI) incorporation (L0, n=3-5) and cleaved caspase 3 expression (L0, n=2-
3). (B) SCCs and FCCs were cultured in 0, 5, or 20 mM 2-deoxyglucose (2DG) for 24 hours. Cell death was 
quantified by flow cytometry through propidium iodide (PI) incorporation (L0, n=3) and cleaved caspase 3 
expression (L0, n=3). Quantification of cleaved caspase 3 and CellTrace signals in cultured hGBM cells after 
24 hours of treatment with rotenone (L0, n=4-5) (C) or metformin (L0, n=4) (D). * p < 0.05, ** p < 0.001, *** p < 
0.0005, one-way ANOVA with Tukey post-test. (E-F) Kaplan-Meier curves showing the survival of animals 
intracranially implanted with SCCs or FCCs (n=4-5) and treated with rotenone (0.5 mg/kg) or fed with a 
glucose-restricted/supplemented high-fat, low-carbohydrate diet (sHFLC) (* p ≤ 0.05, log-rank test). The 
combinatorial effects of administering glucose restriction along with mitochondrial targeting with rotenone 
(n=16, G) or metformin (n=16, H) were measured using CyQUANT assays after 24 hours of treatment (* p < 
0.05, *** p < 0.001, one-way ANOVA with Tukey post-test, ## p < 0.01, t-test). (I) Mean responses predicted by 
the generalized linear models (GLM). The effect of lowering glucose (vertical differences) on cell viability is 
dependent on whether or not metformin or rotenone are present or absent. Interaction p values are indicated. 
 
Figure 5: Elevated lipid metabolite levels and preferential storage of lipid droplets specifically 
metabolized in response to reduced glucose levels in SCCs. (A) PCA and PLS-DA score plots derived 
from UHPLC/HRQMS metabolomics. Green cross: SCCs; red triangle: FCCs. (B) Pathway analysis performed 
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for each individual hGBM cell line revealed that lipids constitute the most represented metabolic intermediates 
that are up-regulated in SCCs compared with FCCs. The majority of lipids up-regulated in SCCs are 
unsaturated (n=3, ** p < 0.01, t-test). (C) Representative fluorescence microscopy images showing, in single 
cells, lipid droplets that were detected using LipidTox (red). SCCs were identified with CFSE-CellTrace (green). 
Nuclei were stained with DAPI (blue). Scale bar, 5mm. (D) Flow cytometry quantification of lipid droplets in 
hGBM L0, L1, and L2 cell lines (n=3-7, *** p < 0.001, t-test). (E) Using flow cytometry, lipid droplet contents 
were compared between cells cultured for 24 hours in high (HG), physiological (PG), or low (LG, 65-80 mg/dL) 
glucose conditions. Results are represented as average percent change relative to HG (n=3 for all lines; * p < 
0.05, t-test compared to HG; # p < 0.05, t-test compared to PG). (F) GSEA of SCC (n=3 biological replicates, 
L0-1-2) and FCCs (n=3 biological replicates, L0-1-2) RNA-seq data sets for enrichment of the autophagosome-
lysosome pathway. FDR, false discovery rate; NES, normalized enrichment score; Nom., nominal. (G) 
Fluorescence microscopy images of LC3 (autophagosome marker) in CellTrace-positive (blue) and negative 
cells. Nuclei were stained with DRAQ5 (red). Scale bar, 5mm. (H) Quantification of LC3 by flow cytometry 
demonstrated greater amounts of autophagosomes in SCCs than in FCCs (L0, n=4; L1, n=4; L2, n=7, ** p < 
0.01, *** p < 0.001, t-test). (I) Confocal microscopy images of lipid droplets (LipidTox, red) and lysosomes 
(LAMP2, green) in a single SCC (CTVhi, blue) and FCC (CTVlo). Top panels represent maximum z-stack 
projections and bottom panels show 3D reconstructions. Scale bar, 5mm. (J) LAMP2 expression was 
measured and compared between SCCs and FCCs by flow cytometry (L0, n=3; L1, n=4; L2, n=4, ** p < 0.01, 
*** p < 0.001, t-test). 
 
Figure 6: Enhanced exogenous fatty acid transport in SCCs. C16-BODIPY uptake was measured using 
flow cytometry (A, time course, second order polynomial non-linear regression fit, L0, n=3; L1, n=3; L2, n=2, 
*** p < 0.0001, two-way ANOVA, MFI: mean fluorescence intensity. B, dose response, L0, n=3; L1, n=6; L2, 
n=3, *** p < 0.0001, linear regression). 
 
Figure 7: Inhibition of lipid uptake and resistance to glucose restriction following FABP blockade in 
SCCs. (A) GSEA comparing RNA sequencing results between SCCs and FCCs (n=3 biological replicates, L0-
1-2) for the fatty acid metabolism gene signature. FDR, false discovery rate; NES, normalized enrichment 
score; Nom., nominal. (B) Results for qRT-PCR of genes differentially expressed between SCCs and FCCs 
using the RT2 Profiler PCR Array for Human Fatty Acid Metabolism. Changes in transcript levels are given as 
percent change relative to FCCs (n=3-8, p < 0.05, one sample t-test). (C) FABP7 expression in brain (n=4), 
breast (n=336), colorectal (n=374), lung (n=117), ovarian (n=242), and pancreatic (n=20) cancer cell lines (**, 
p < 0.005, ****, p < 0.0001, one-way ANOVA). (D) Evaluation of the Bredel dataset indicated higher expression 
of FABP7 in glioblastoma (n=27) compared to non-malignant (n=4) brain tissue (**, p < 0.005, t-test). (E) Data 
from the Shai database showed greater FABP7 expression in GBM (n=27) versus astrocytoma (n=5) (***, p < 
0.001, one-way ANOVA, #, p < 0.05, t-test). Kaplan-Meier curves derived from TCGA (F) and Freij-affy-human-
91666 (G) datasets indicated that high expression of FABP7 (red) correlated with poorer patient survival 
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compared to the low FABP7-expressing group (green). ** p<0.01, *** p<0.001, log-rank test. (H) 
Immunofluorescence microscopy images of a representative single SCC (CFSE-CellTrace positive, green) and 
FCC (CellTrace negative) labeled for FABP7 (red). Nuclei were stained with DAPI (blue). Scale bar, 5mm. (I) 
Flow cytometry analysis demonstrated that SCCs overexpress FABP7 compared to FCCs (L0, n=2; L1, n=2; 
L2, n=3, * p < 0.05, *** p < 0.001, t-test). (J) C16-BODIPY uptake was measured in L1 GBM line SCCs or 
FCCs cultured with or without 200 nM FABP7 inhibitor (FABP7i, each condition, n=3, *** p < 0.0001, linear 
regression). (K) L1 SCCs and FCCs were separated by FACS and cultured in high glucose or physiological 
glucose (PG) conditions, with or without 200 nM FABP7 inhibitor. Cell proliferation was assessed using 
CyQUANT assays 5 days after treatment (n=2-3, * p < 0.05, one-way ANOVA with Tukey post-test). (L) C16-
BODIPY uptake was measured in the L1 wild-type (WT) and CRISPR-FABP7 (crFABP7) cell line (each 
condition, n=3, * p < 0.05, linear regression). Cell death of the crFABP7 cell line in the absence or presence of 
5 mM 2-deoxyglucose (2DG) was quantified by flow cytometry 24 hours after treatment through propidium 
iodide (PI) incorporation (n=3) (M) and cleaved caspase 3 expression (n=3) (N). (O) Kaplan-Meier curves 
showing the survival of animals intracranially implanted with L2 GBM patient-derived cell line and treated with 
15 mg/kg i.p. of the FABP7 inhibitor (FABP7i) once a week for 3 weeks and 500 mg/kg of 2-deoxyglucose (2-
DG) twice a week for 4 weeks, or a combination of both (n= 5 per group, * p ≤ 0.05, log-rank test). (P) 
Predicted survival curves using the Cox frailty model fit and grouping the results for L0, L1, and L2 xenografts 
subjected to the different experimental conditions (* p ≤ 0.05, ** p ≤ 0.01, log-rank test). (Q) Predicted survival 
curves using the Cox frailty model fit and grouping the results for L0, L1, and L2 xenografts with or without 
treatment with the FABP7 inhibitor (*** p ≤ 0.001, log-rank test).   
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Supplementary data 
Figure EV1: (A) GSEA of SCC (n=3 biological replicates, L0-1-2) and FCC (n=3 biological replicates, L0-1-2) 
RNA-seq data sets for enrichment of the stem cell gene signature	(Wong et al., 2008). FDR, false discovery 
rate; NES, normalized enrichment score; Nom., nominal. (B) SCCs and FCCs were separated 6-8 days after 
(CFSE or CTV) CellTrace loading. Gates were set as 10% CellTracehi vs. CellTracelo). (C) Threshold images of 
human specific nestin staining were used for quantification of tumor invasion (n = 5 animals per group, see 
Methods). (D) Immunofluorescence imaging revealed notable differences between invasive, SCC-derived, and 
non-invasive, FCC-derived, tumors. Invasive SCC-derived tumors were positive for ZEB1 (green), while this 
marker was absent in the tumor masses derived from FCCs. Tumor cells were labeled with hNestin (red) and 
nuclei with Hoechst (blue). (E) Fluorescence imaging showed that the invasion of ZEB1 knockdown (shZEB1) 
SCC-derived tumors from orthotopic xenografts was greatly reduced compared to that of control SCC-derived 
tumors (shCo). Scale bars 10 µm. Temozolomide-resistant cells (TMZR) and SCCs derived from the L1 patient-
derived GBM line displayed similar growth rate (n=3) (F), TMZ sensitivity (n=6-8, * p < 0.05, *** p < 0.001, one-
way ANOVA with Tukey post-test) (G), as well as migration (H) and invasion (I) (n=3-12). These results were 
accompanied by the detection of high expression levels of ZEB1 in TMZR-derived tumors (J).   
 
Figure EV2: (A) The use of Search Tool in the Retrieval of Interacting Genes/Proteins database (STRING) 
indicated an over-representation of genes associated with lipid metabolism in recurrent GBMs. Red nodes 
designate the response to lipid genes (n = 56) that are significantly overexpressed in recurrent GBMs within 
the entire network of genes. Gene networks involved in oxidation-reduction (B) and anti-oxidant processes (C) 
are up-regulated in recurrent tumors. (D) Cells from single cell RNA sequencing data were classified into slow 
(SCC) and fast-cycling (FCC) clusters based on the relative expression of cell cycle G1/S (x axis) and G2/M (y 
axis)-associated gene sets. (E) GSEA of SCC (n=3 biological replicates, L0-1-2) and FCC (n=3 biological 
replicates, L0-1-2) RNA-seq data sets for enrichment of the lipid gene signature identified in TCGA rGBM and 
our three GBM-derived SCCs. FDR, false discovery rate; NES, normalized enrichment score; Nom., nominal. 
 
Figure EV3: (A) Electron microscopy images of SCCs and FCCs from L1 and L2 patient-derived GBM cell 
lines showing greater number of mitochondria in SCCs than FCCs. (B) Raw values of mean fluorescence 
intensity (MFI) following MitoTracker Green staining in SCCs and FCCs derived from hGBM L0 (n=10), L1 
(n=13), and L2 (n=6). (C) Raw values of mean fluorescence intensity (MFI) following MitoTracker Orange 
staining in SCCs and FCCs (L0, n=9; L1, n=2; L2, n=6). (D) Raw values of mean fluorescence intensity (MFI) 
in SCCs and FCCs following the MitoProbe DilC1 assay (L0, n=4; L1, n=2; L2, n=5). Oxygen consumption rate 
(OCR) measured using the XF Cell Mito Stress Assay (E) and ATP production measured using the luciferase-
based ATP-lite assay (F) in SCCs and FCCs (L0, n=18; L1, n=15; L2, n=15, * p < 0.05, ** p < 0.01, t-test). 
 
Figure EV4: (A) SCCs and FCCs were cultured in high glucose (HG, > 500 mg/dL) or physiological glucose 
(PG, 90-110 mg/dL) conditions for 24 hours. Cell death was quantified by flow cytometry through propidium 
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iodide (PI) incorporation (L1, n=2; L2, n=4) (A) and cleaved caspase 3 expression (L1, n=2; L2, n=3) (B) SCCs 
and FCCs were cultured in 0, 5, or 20 mM 2DG for 24 hours and cell death quantified by flow cytometry 
through propidium iodide (PI) incorporation (L1, n=2; L2, n=4) and cleaved caspase 3 expression (L1, n=2; L2, 
n=3). (C) Using RT-qPCR, expression levels of the isoforms A, B, and C of lactate dehydrogenase were 
compared between SCCs and FCCs (n=3 technical replicates for each line) of the three hGBM cell lines. 
Changes in transcript levels are given as the mean percent change relative to FCCs. * p < 0.05, *** p < 0.001, 
one sample t-test. The combinatorial effect of administering glucose restriction and mitochondrial targeting with 
rotenone (n=16, D) or metformin (n=16, E) was measured using the CyQUANT assay after 24 hours of 
treatment for L0 and L2 hGBM cell lines (* p < 0.05, *** p < 0.001, one-way ANOVA with Tukey post-test, ## p < 
0.01, t-test).  
 
Figure EV5: List of all the pathways up-regulated in the SCCs, based on metabolites that are over-represented 
in SCCs compared to FCCs (fold change ≥ 2). 
 
Figure EV6: (A) Raw values of mean fluorescence intensity (MFI) in SCCs and FCCs following LipidTox 
staining. GSEA of SCC and FCC RNA-seq data sets for enrichment of the autophagosome-lysosome 
signature, as defined by Perera et. al. (Perera et al., 2015) (B) and Jegga et. al. (Jegga et al., 2011) (C). FDR, 
false discovery rate; NES, normalized enrichment score; Nom., nominal. Raw values of mean fluorescence 
intensity (MFI) in SCCs and FCCs following immunostaining for LC3B (D) and LAMP2 (E). 
 
Figure EV7: (A) FABP7 protein expression in normal brain tissue (A) and glioma (B), image credit: Human 
Protein Atlas v16.1, www.proteinatlas.org. (C) GSEA of SCC (n=3 biological replicates, L0-1-2) and FCC (n=3 
biological replicates, L0-1-2) RNA-seq data sets for enrichment of FABP7-correlated genes. FDR, false 
discovery rate; NES, normalized enrichment score; Nom., nominal. (D) C16-BODIPY uptake in control 
conditions or with 250 nM of FABP3 inhibitor (BMS309403) (n=3, *** p < 0.0001, linear regression). (E) FAC-
sorting of least and most intense GFP-positive single cells and representative immunofluorescence microscopy 
images of FABP7 immunoreactivity in wild-type (clone D5 WT) and crFABP7 (clone H7) clones following 
CRISPR/Cas9 plasmid transfection for FABP7. FABP7 fluorescence mean intensity (FMI) was higher in wild-
type than crFABP7 clones as measured by flow cytometry. FABP7 expression was assessed using two 
different antibodies (clone AF3166 and clone sc-300-88). Nuclei were labeled with DAPI. 
 
Figure EV8: (A) Total and SCC populations were treated with FABP7i concentrations ranging from 5 nM to 10 
µM. In L0 and L1, 1 and 10 µM concentrations of FABP7i significantly reduced the migration distances of 
overall unsorted and SCC populations, whereas only 10 µM FABP7i was significant for L2 SCC (* p < 0.05, ** 
p < 0.001, *** p < 0.0005, one-way ANOVA with Tukey post-test). (B) In vivo inhibition of FABP7 also resulted 
in decreased tumor cell invasion. The effects of FABP7 inhibition, alone or in combination with pharmacological 
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targeting of glycolysis with 2-DG, were conducted on tumors derived from the xenotransplants of L1 (C) and L0 
(D) GBM patient-derived cells lines.  
 
Table EV1: Complete list of genes differentially expressed between primary and recurrent GBMs and identified 
from the TCGA dataset.  
 
Table EV2: List of pathways up-regulated in recurrent tumors and identified using the STRING platform 
(Szklarczyk et al., 2015) (http://string-db.org).  
 
Table EV3: List of genes up-regulated in recurrent GBMs that directly regulate or are associated with genes 
regulating Oxphos metabolism. 
 
Table EV4: List of genes up-regulated in primary GBMs that directly regulate or are associated with genes 
regulating glucose metabolism. 
 
Table EV5: List of genes included in the Oxphos gene sets 
(GO_REGULATION_OF_OXIDATIVE_PHOSPHORILATION) and Glycolysis gene set 
(KEGG_GLYCOLYSIS_GLUCONEOGENESIS). 
 
Table EV6: List of identified metabolites that are over-represented in SCCs (fold change > 2). 
 
Table EV7: List of genes constituting the autophagosome-lysosome signature. 
 
Table EV8: List of primers used for qRT-PCR. 	
Table EV9: List of genes constituting the lipid metabolism gene set 
(http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-007A.html) compared by GSEA between SCCs 
and FCCs. 	
Table EV10: List of genes positively correlated with FABP7 in human glioma identified using the Data 
Visualization Tools for Brain Tumor Datasets (GlioVis, http://gliovis.bioinfo.cnio.es/). 
 
Table EV11: List of genes differentially expressed between SCCs and FCCs (Single cell RNA sequencing 
analysis) (Venteicher et al., 2017) defined by cell cycle gene expression as described by Tirosh and colleagues 
(Tirosh et al., 2016a, Tirosh et al., 2016b). The results demonstrate over-expression of FABP7 in SCCs.  
